Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Twentyeight-Seven Therapeutics raises $65mm via Series A round

Executive Summary

Oncology start-up Twentyeight-Seven Therapeutics Inc. (28-7) raised $65mm through its Series A round from investors including MPM Capital and Novartis Venture Fund (co-leads), along with Johnson & Johnson Innovation – JJDC, Inc., Vertex Ventures HC, Longwood Fund, and Astellas Venture Management.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies